Vericel (VCEL) Tops Q3 EPS by 9c, Revenues Beat; Raises FY18 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to Vericel (VCEL) Tops Q3 EPS by 9c, Revenues Beat; Raises FY18 Revenue Guidance Above Consensus

Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance

November 6, 2018 7:30 AM EST

58% Revenue Growth Over Third Quarter 2017

Conference Call Today at 8:30am Eastern Time

CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2018 and raised its full year 2018 revenue guidance.

Third Quarter 2018 Financial Highlights

Total net revenues increased 58% to $22.5 million compared to $14.3 million in the third quarter... More